The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Papillary and follicular thyroid cancers are considered well-differentiated cancers. Papillary thyroid cancer is the most prevalent type of thyroid cancer--with over 50,000 new cases per year in the ...

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

GLP-1 agonist initiators had a significantly higher likelihood of undergoing thyroid ultrasonography at 6 and 12 months, suggesting detection bias was behind the increased cancer diagnosis rate ...

In terms of histology, this endocrine malignancy predominantly comprises papillary thyroid cancer and follicular ... triphosphate-binding proteins of the Ras and Rho families.

1. Papillary thyroid cancer is the most prevalent (80%), slow-growing, and frequently curable. Variants that grow more quickly, such as tall cells and columnar, may require more intensive treatment.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Brito, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues estimated the risk for incident thyroid cancer among adults with type 2 diabetes being treated with GLP-1 RAs vs other ...